Stock prices were mutedly up in London at the open on Friday, while inflation in Germany cooled and Barclays announced plans to buy Tesco Bank?s retail banking business.The FTSE 100 index opened up 5.17 points, 0.1%, at 7,600.65. The FTSE 250 was marginally up 2.72 points at 19,105.44, and the AIM All-Share was up 0.52 of a point, 0.1%, at 751.62.The Cboe UK 100 was up 0.1% at 760.08, the Cboe UK

Polymetal shares slump as it forges ahead with Kazakhstan moveAlmost certain to result in de-listing from LondonMove seen as crucial to escape sanctions and counter-sanctions linked to Ukrainian conflictRussian and Kazakh gold miner Polymetal (POLY) saw its share price battered as it confirmed plans to move its domicile from Jersey to Kazakhstan to escape sanctions and counter-sanctions from the o

JD WetherspoonInvestors will be looking for signs pubs group's sales momentum is poised to pick up in the second halfPubs group JD Wetherspoon (JDW) is scheduled to release first half results to 29 January 2023 on 24 March. The shares have had a strong run since last October gaining around 38% on the back of a general market recovery.A January trading update said first half like for like sales gre

Nine months on from Russia's invasion of Ukraine and the fate of many Russia-focused stocks and funds remain up in the air.High profile names have fallen by the wayside - notably Russian gold miner Petropavlovsk.Prevented from selling its gold due to sanctions, the company entered administration and exited the UK stock market in July leaving shareholders with nothing. Real estate group Raven Prope

- UK approval granted for COV19-ID test kit- Fastest test on the market- Commercial progress outside the UKPoint-of-care molecular diagnostics company Genedrive (GDR:AIM) has received approval from the UK Medicines and Healthcare Products regulatory authority for its COV19-ID kit to be marketed and sold in the UK.Under CTDA (Coronavirus Test Device Approvals) regulations introduced in July 2021 Ge

Point of care molecular diagnostics company Genedrive (GDR:AIM) has entered into several distribution agreements for its rapid Covid-19 test-kit. The test, which received CE accreditation in early December 2021, means it can now be sold across Europe.Genedrive shares surged in early trading as investors got very excited about the implied revenue growth potential, the stock jumping as much as 35% b

News of the fresh Omicron variant of Covid put a rocket under biotechnology shares which have pioneered novel mRNA vaccines.Biotechnology firms Moderna and BioNTech surged 21% and 14% respectively when the news broke last Friday (26 Nov) while the share price movements in AstraZeneca (AZN), Pfizer and Johnson & Johnson were far more muted as the table shows.The reason Moderna and BioNTech outperfo

Oil prices rallied hard on Monday as investors bet on speculation that major produces, the cabal known as OPEC+, may pause an output increase in response to the spread of the new Omicron Covid variant.That helped the benchmark FTSE 100 add 66 points, or about 0.94% at 7,109.95 as oil giants BP (BP.) and Royal Dutch Shell (RDSB) added more than 3% and 2% respectively to finish at 328.35p and £15.9

Shares in molecular diagnostics company Genedrive (GDR:AIM) surged 80% higher on Monday to 41.7p after it said it had submitted a new point of care rapid Covid-19 test for approval in Europe.The company said its kit represents a 'step-change' in rapid testing and provides a positive test result within 7.5 minutes and a negative test result with 17 minutes.In relation to the latest variant of conce

Many investors only look at the UK stock market for opportunities, but in doing so they would be missing out from a much bigger pool of interesting companies listed on overseas markets.Some of the world's leading companies trade on stock markets outside of the UK, including retail giant Amazon, German carmaker Volkswagen, Swiss food producer Nestle and US consumer electronics giant Apple.Most main

The successful development of vaccines was a triumph for the world and was for the most part great news for equities too, however it negatively impacted sentiment for one particularly sub-set of the market.The initial excitement surrounding biotechnology companies involved in developing Covid-19 testing kits and treatments for sufferers of coronavirus rapidly evaporated as the focus moved from tes

Leading UK stocks reversed earlier gains to fall at the finish on Monday, with the FTSE 100 retreating but managing to stay above 7,000 by the skin of its teeth. The UK's benchmark lost 0.3% to end the day at 7,000.08, while the FTSE 250 nudged 0.1% lower to close at 22,490.86, easing off its record finish on Friday.It was a largely dull day for company news with attention very much grabbed by the

A quiet morning for UK shares belies the action and outrage in the football world, and thousands of investors will be closely watching Wall Street's opening bell to see how Manchester United's New York-listed stock trades after the ructions of its decision to join a breakaway European Super League.Shares in Italian club Juventus, also one of the breakaway dozen, saw its stock jump 14% on Monday.Le

Shares in diagnostics firms Genedrive (GDR:AIM) and Yourgene Health (YGEN:AIM) were in demand on Monday after announcing success with their respective tenders into Public Health England's National Microbiology Framework for diagnostic goods and services.The framework agreement which is worth up to £3 billion opened in November 2020 and sought to appoint suppliers of clinical laboratory diagnostic

UK stocks made modest gains in early trading on Monday, edging higher as investors continued to bet on a global economic recovery with vaccine rollouts gathering pace.By 8.32 am, London's FTSE 100 was up 0.06% at 7,023.92 points, consolidating its position above 7,000 as investors balanced reopening optimism with a need to take stock following recent gains, while the FTSE 250 crept 0.26% higher to

The announcement of second lockdown measures in England gave biotechnology shares involved in Covid-19 testing another a boost with Avacta (AVCT:AIM), Omega Diagnostics (ODX:AIM), Genedrive (GDR:AIM) all registering gains.However these moves were overshadowed by the 110% gain in gene cell engineering company [bold] Horizon Discovery (HZD:AIM) and the 75% gain in blood flow monitoring firm LiDCO (

The FTSE 100 opened weaker on Friday for a fourth straight day of decline, dropping 0.4% to 6,026 as record spikes of virus infections in Hong Kong and Tokyo fuelled fears of a second wave hitting Asia. In the US death rates hit record levels in the states of Florida, Arizona, Texas and California.Trading across Asia was weak with the Nikkei 225 giving up 1% and China's Shanghai Composite down 1.8

Having delivered some of the best performances in the stock market so far in 2020, biotechnology shares have encountered a brutal correction over the last few weeks.Investors might be feeling bruised after seeing in some cases shares losing over half of their values, while on average they have dropped just over 40% in value from recent highs, as the table shows.Part of this downdraft is probably t

UK biotechnology shares have provided some of the best returns in the market over the last six months, driven by a plethora of regulatory news about new products aimed at tackling coronavirus.Shareholders are rightly asking whether the strong share price performances have gone too far in relation to the fundamentals, or maybe in some cases have further to run. We will now talk through the importan

There are many ways to build a list that ranks the most important companies to people. In its most straightforward sense, for investors that are still in work, your employer or own business is almost certainly the most important company to you since they provide your source of income and contribute to your pension savings too.Those in retirement might equally argue the case for the holder of their